MedWatch

US government exercises option to buy Bavarian smallpox vaccines for USD 119m

The first option in an existing contract with the US has been utilized, and Bavarian Nordic can start manufacturing freeze-dried doses of Jynneos for the country in 2023.

Photo: Bavarian Nordic / PR

The US Biomedical Advanced Research and Development Authority (BARDA), which falls under the US Department of Health and Human Services, has exercised an option in a contract with Danish vaccine firm Bavarian Nordic, the firm has announced in a Wednesday press release.

The option is valued at USD 119m, and means that Bavarian can start manufacturing its first doses of its freeze-dried version of Jynneos, a smallpox vaccine, in 2023 and 2024.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs